Arcellx Inc. (ACLX) Financial Statements (2025 and earlier)

Company Profile

Business Address 800 BRIDGE PARKWAY
REDWOOD CITY, CA 94065
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:702,017254,800
Cash and cash equivalents394,58364,179
Short-term investments307,434190,656
Other undisclosed cash, cash equivalents, and short-term investments  (35)
Restricted cash and investments1,9032,501
Other undisclosed current assets12,4439,562
Total current assets:716,363266,863
Noncurrent Assets
Operating lease, right-of-use asset27,09928,659
Property, plant and equipment42,72811,231
Long-term investments and receivables27,168 
Long-term investments27,168 
Prepaid expense9,3564,563
Restricted cash and investments2,4182,501
Total noncurrent assets:108,76946,954
TOTAL ASSETS:825,132313,817
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,92120,732
Accounts payable2,6199,053
Accrued liabilities18,30211,679
Deferred revenue50,533 
Debt39,28333,060
Other undisclosed current liabilities7,5012,901
Total current liabilities:118,23856,693
Noncurrent Liabilities
Long-term debt and lease obligation  20,871
Finance lease, liability  20,871
Liabilities, other than long-term debt221,51431,299
Deferred revenue170,673 
Other liabilities  
Operating lease, liability50,84131,299
Total noncurrent liabilities:221,51452,170
Total liabilities:339,752108,863
Equity
Equity, attributable to parent485,380204,954
Common stock5244
Additional paid in capital874,261523,921
Accumulated other comprehensive income (loss)547(221)
Accumulated deficit(389,480)(318,790)
Total equity:485,380204,954
TOTAL LIABILITIES AND EQUITY:825,132313,817

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
Revenues110,319 
Gross profit:110,319 
Operating expenses(200,199)(191,259)
Operating loss:(89,880)(191,259)
Nonoperating income
(Other Nonoperating income)
19,8532,580
Interest and debt expense(3,846)(1,720)
Loss from continuing operations before equity method investments, income taxes:(73,873)(190,399)
Other undisclosed income from continuing operations before income taxes3,846 
Loss from continuing operations before income taxes:(70,027)(190,399)
Income tax expense(663) 
Net loss:(70,690)(190,399)
Other undisclosed net income attributable to parent  1,720
Net loss available to common stockholders, diluted:(70,690)(188,679)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
Net loss:(70,690)(190,399)
Comprehensive loss:(70,690)(190,399)
Other undisclosed comprehensive income, net of tax, attributable to parent7681,519
Comprehensive loss, net of tax, attributable to parent:(69,922)(188,880)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: